key: cord-0894036-cgvaqoqn
authors: Heudel, P.; Favier, B.; Solodky, M.-L.; Assaad, S.; Chaumard, N.; Tredan, O.; Bachelot, T.; Ray-Coquard, I.; Russias, B.; Fournier, M.-L.; Mastroianni, B.; Avrillon, V.; Michallet, A.-S.; Zrounba, P.; Chabaud, S.; Perol, D.; Blay, J.-Y.
title: Survival and risk of COVID-19 after SARS-COV-2 vaccination in a series of 2391 cancer patients
date: 2022-02-10
journal: Eur J Cancer
DOI: 10.1016/j.ejca.2022.01.035
sha: 78d93bb577e0c25687914b86fbd42ebf8c3a666c
doc_id: 894036
cord_uid: cgvaqoqn

BACKGROUND: Patients with cancer are at high risk for severe or lethal CoVID-19. The impact of SARS-COV-2 vaccination on the risk of developing COVID-19 was investigated in an exhaustive series of patients from a comprehensive cancer center. METHODS: This is a study of the exhaustive population of 2391 cancer patients who were prescribed SARS-COV-2 vaccination until 09/21. Patient characteristics, documented SARS-COV-2 infection with RT-PCR, and survival were collected. The primary endpoint was the rate of COVID-19 after vaccination. Secondary endpoints included risk factors to develop COVID-19 after vaccination, with a comparison with the cohort of vaccinated health care workers (HCW), and risk factors for death. RESULTS: From Jan to Sept 2021, among 2391 patients with cancer under active treatment in whom a SARS-COV-2 vaccine was prescribed, 659 (28%), 1498 (63%) and 139 (6%) received 1, 2 and 3 doses respectively. 95 patients received a single dose of vaccine after a previous COVID-19. 2285 health care workers (HCW) received one (N=17, 0.7%), 2-3 (N=2026, 88.7%) vaccine doses and one dose after COVID-19 (N=242, 10.6%). With a median follow-up of 142 and 199 days for patients and HCW respectively, 39 (1.6%) patients and 35 (1.5%) HCW developed COVID-19 after vaccination. 6 of 39 cancer patients and no HCW died because ofCOVID-19 within 50 days after diagnosis. Independent risk factors for COVID-19 in vaccinated patients were age, single dose of vaccine without previous COVID-19 and anti-CD20 treatment in the last 3 months. Independent risk factors for death included metastatic disease, gender, cancer type, but also documented COVID-19 before vaccination. CONCLUSIONS: Patients receiving two or more doses of COVID-19 vaccine have reduced risk of COVID-19. The risk of death of vaccinated cancer patients presenting COVID-19 remains high. COVID-19 before vaccination is associated with an increased overall risk of death.

Patients with cancer are at high risk for severe or lethal CoVID-19. The impact of SARS-COV-2 vaccination on the risk of developing COVID-19 was investigated in an exhaustive series of patients from a comprehensive cancer center.

This is a study of the exhaustive population of 2391 cancer patients who were prescribed SARS-COV-2 vaccination until 09/21. Patient characteristics, documented SARS-COV-2 infection with RT-PCR, and survival were collected. The primary endpoint was the rate of COVID-19 after vaccination. Secondary endpoints included risk factors to develop COVID-19 after vaccination, with a comparison with the cohort of vaccinated health care workers (HCW), and risk factors for death.

From Jan to Sept 2021, among 2391 patients with cancer under active treatment in whom a SARS-COV-2 vaccine was prescribed, 659 (28%), 1498 (63%) and 139 (6%) received 1, 2 and 3 doses respectively. 95 patients received a single dose of vaccine after a previous COVID-19. 2285 health care workers (HCW) received one (N=17, 0.7%), 2-3 (N=2026, 88.7%) vaccine doses and one dose after COVID-19 (N=242, 10.6%). With a median follow-up of 142 and 199 days for patients and HCW respectively, 39 (1.6%) patients and 35 (1.5%) HCW developed COVID-19 after vaccination. 6 of 39 cancer patients and no HCW died because ofCOVID-19 within 50 days after diagnosis. Independent risk factors for COVID-19 in vaccinated patients were age, single dose of vaccine without previous COVID-19 and anti-CD20 treatment in the last 3 months. Independent risk factors for death included metastatic disease, gender, cancer type, but also documented COVID-19 before vaccination.

Cancer patients are at high risk of death from COVID-19, with a 28-day mortality rate after documented SARS-COV-2 infection with RT-PCR ranging from 10 to 38% (1) (2) (3) (4) (5) (6) (7) (8) (9) .

This increased risk of death is observed in all cancer types, of all stages (1) (2) (3) (4) (5) (6) (7) (8) (9) , but has been reported to be higher in patients with associated comorbidities, with advanced lung cancer, in patients with hematological malignancies, in particular those treated with anti-CD20 Ab, in patients with lymphopenia, and a biological inflammation profile with CRP increase in particular (4) (5) (6) (7) (8) (9) (10) (11) (12) (13) (14) .

This increased risk of death is considered to result from immunodepression and inflammation associated with cancer as well as from cytotoxic and immunomodulating treatments, resulting in defective B and T cell response against SARS-COV-2 (10) (11) (12) (13) (14) . Lymphopenia is consistently associated with a worse outcome after COVID-19 infection in cancer patients (4, 6, 7, 8) Vaccination with mRNA based or recombinant virus vaccines have been shown to reduce the risk of documented SARS-COV-2 infection with long lasting protection in the general population (15) (16) (17) (18) . The protective effect of SARS-COV-2 vaccines have also been demonstrated in cancer patients in relatively small sized series (19) (20) (21) (22) , although cancer patients develop less efficient antiviral immune response after vaccination (23) (24) (25) (26) . In a series of 1503 patients reported from our center, we reported on a higher incidence of COVID-19 in patients who received only one vaccine dose (21) . The impaired immune response observed in general in frail patients prompted researchers to investigate additional strategies for immunization. An additional vaccination boost has been proposed in transplanted patients with encouraging results (26) (27) (28) (29) (30) . Heterologous vs homologous boosts were also tested and reported to yield similar antibody response in patients without cancers (27) . A single dose of vaccine has been found to be efficient in patients who recovered from symptomatic COVID-19 infection (231).

Whether these strategies are efficient in cancer patients is still unclear. To address these questions, 

The information on vaccination and patient characteristics were collected from the electronic patient records (EPR) with the CONSORE tool as previously described (32), see also https://www.swordgroup.com/en/news/projet-consore ). ConSoRe is a new data analytics solution aggregating diverse forms of structured and unstructured data extracted from EPR and structuring cancer management for all patients. It uses natural language processing to search aggregated data and perform advanced data mining. This tool enables the collection of clinical information integrated to the electronic patient record; these were subsequently validated manually if inconsistent data were collected. The EPR of all patients consulting the institution from Jan 2021 to Oct 2021 were screened. The EPR system of the CLBs includes a standard set of data (e.g. tumors characteristics, treatments, vaccines, deaths) as well as information present only in unstructured data sources. The extracted relevant structured data was integrated in Excel files.

The cumulative incidence of COVID-19 in the 2285 vaccinated health care workers of the same institute was calculated from the date of the first vaccine dose, and analyzed according to the Three opted out. Conversely, 6 HCW whom data were not declared at the OMD department (fellows, recent hiring) requested to participate.

The following data were collected for cancer patients: demographic characteristics (age, weight, body mass index, gender, tobacco…), cancer characteristics (histotypes, primary site, stage), previous cancer treatments in the last months, dates and types of vaccines, patient outcome (date of documented SARS-COV-2 infection, survival, last news). Only dates of vaccinations, dates of documented RT-PCR+ for SARS-COV-2 were analyzed for HCW. Only RT-PCR+ documented SARS-COV-2 infections were retained as events.

The distribution of clinical characteristics was analyzed using Chi-squared test, Fisher exact test, Mann-Whitney U test. Survival was plotted from the date of the first dose (or for some analyses, Table 1 describes the clinical characteristics of the patients according to the number of vaccines doses received. A significantly larger proportion of female patients, of smokers, of patients with hematological malignancies, receiving anti-CD20 received 2 or 3 doses of vaccines (Table 1 ). In the same hospital, 2285 Health Care workers (HCW) were vaccinated for COVID-19, with one (N=259, 11.3%) or 2-3 doses (N=2026, 88.7%). In France, vaccination is mandatory by law for all active HCW.

We first compared the incidence of COVID-19 after a first vaccine dose in cancer patient to that Table 1 ). Figure 1B Figure   1D ). In the group of HCW, a single vaccine dose was also associated with an increased risk of post vaccination COVID-19 (not shown). In cancer patients, no significant difference was observed between the four vaccines products used for the first dose ( Figure 1E , logrank=2.5, p=0.47). No significant differences were observed for patients vaccinated twice or more with homologous or heterologous vaccines ( Figure 1F, logrank=0.16, p=0.68) .

A multivariate analysis was conducted to determine independent risk factors for developing a documented COVID-19 after a first vaccination. Cancer histotype, primary site,stage, age, gender, anti-CD20 treatment, number of vaccine doses (1 vs 2 vs 3), comorbidities (obesity, smoking) were tested in univariate analysis. Significant risk factors in univariate analysis i.e. age, anti-CD20, number of vaccine doses>1 and smoking were included as covariates in the multivariate model. Age younger than 60, treatment with anti-CD20 in the last 3 months, and a single vaccine dose were independently associated with increased risk of COVID-19 (Table 2 ). Of note, there was a significantly larger proportion of patients aged above 60 who had received 3 vaccine doses (97/1304 [6.9%] vs 42/948 [4.2%], p=0.006). The same 3 parameters were retained by the model when the multivariate analysis was conducted with a landmark analysis of 21 days (not shown). In patients who received 2 or 3 vaccines or a single dose after a documented Covid-19, younger age (<60) and treatment with anti-CD-20 in the last 3 months were retained as independent risk factors (not shown).

The survival of the 39 cancer patients with documented COVID-19 after vaccination was then explored. Figure 2A There were respectively 43/616 (5.5%), 95/1403 (6.3%),7/132 (5.0%), 9/86 (9.5%) reported deaths in patients who had received 1, 2, 3 and 1 dose of vaccine post COVID-19 respectively. We investigated the overall survival from the first vaccination dose for patients who developed or not COVID-19

infection. Cumulative risk of death was numerically higher in the group of patients who were diagnosed with COVID-19 after vaccination ( Figure 2B ). In Figure 2B (Table 2) . Documented COVID-19 before vaccination was associated with an hazard ratio for death of all causes of 2.187 (Table 2 ).

This series describes the efficacy of COVID-19 vaccine program in a real-life population of 2391 cancer patients treated in a comprehensive cancer center. It shows the efficacy of the full vaccination program in a large cohort of cancer patients, and also indicates that COVID-19 remains a significant risk factor for death of cancer patients even in the 6 months following vaccination. Pre-vaccination COVID-19 was also identified as an independent risk factor for death in this population. The significantly larger proportion of patients aged above 60 who had received 3 vaccine doses is also likely to contribute to these observations. Of note, there were no significant difference in the types of vaccine given to patients aged<60 and >=60 (data not shown).

High mortality was however observed for cancer patients presenting with a COVID-19 after vaccination, with a 17.6% cumulative risk of death at day 50. Indeed, 6 of the 39 cancer patients died in the 50 days post documented RT-PCR. Conversely, none of the 35 HCW presenting with documented COVID-19 died, with one requiring a short hospitalization. In cancer patients, COVID-19 after vaccination remains a disease with a high risk of death in cancer patients. It is therefore essential to maintain precautions (masks, social distancing) in hospitalization and during all steps of cancer patient management. Third vaccination dose may also be recommended, since none of the 139 patients who received a third dose so far presented a COVID-19 after vaccination with the limit of the short followup discussed above. It is also important to note that no COVID-19 was observed either in patients who received a single vaccine dose after a documented episode of COVID-19 before vaccination.

Several parameters were found independently correlated with the risk of death from any cause in this population of vaccinated cancer patients. As expected, the presence of a metastatic disease was independently associated with a higher risk of death, but others such as male gender and hematological malignancy were not necessarily expected. For hematological cancer, this may reflect the aggressive natural history of these diseases as compared to the other neoplasia, but also most likely the frequent use of anti-CD20 for B cell malignancies. Though anti-CD20 treatment was not found J o u r n a l P r e -p r o o f correlated to overall survival, it is identified as an independent risk factor for post vaccination COVID-19, which are associated with a high mortality as discussed above.

Surprisingly a documented previous COVID-19 infection before the single vaccine dose was also associated with an increased risk of death in this series. The medical explanation of this observation remains unclear, but similar findings were recently reported for cancer patient series with a previously documented COVID-19 (33) . Cancer patient remain fragile for a long period of time after COVID-19 and therefore remain at higher risk of complications or death, in particular patients with long lasting symptoms (33) . In the present study, documented COVID-19 before the first vaccine dose was associated with a hazard ratio for death of all causes above 2, while none of these patients presented The results presented in this study are consistent with previous reports showing the importance of a full vaccination program (19) (20) (21) (22) . It is consistent with the reports of the value of a third vaccines both in terms of clinical efficacy and immunological response (26) (27) (28) (29) (30) 35, 36) . It further indicates the severity of the rare post-vaccination COVID-19 in cancer patients, with a mortality rate of post-vaccination COVID-19 which is not different from that of non-vaccinated patients (1) (2) (3) (4) (5) (6) (7) (8) (9) . The immunosuppression associated with cancer, and cancer treatments, are correlated to a less efficient immune response in other studies, with baseline lymphopenia, and inadequate Ab response or T cell response now well documented for these patients (1) (2) (3) (4) (5) (6) (7) (8) (9) (23) (24) (25) (26) . The present report indicates that cancer patients remain at high risk of death when presenting a documented COVID-19 and should persist on protective measures, within and outside the hospital.

This study has several limitations. It focuses on patients in whom vaccination was prescribed in the center and does not take in account patients vaccinated outside the center. This is not a randomized study testing the value of the number of vaccine doses, which would be needed to demonstrate the impact of the number of vaccine doses, in particular the third dose, in the population of cancer patients (26) . For the survival analyses, not all informations of comorbidities were collected, eg cardiovascular disease or diabetes. The CONSORE tool has limitations for the collection of information on follow-up and require manual verification when data are missing or inconsistent (32). As a descriptive real-life study, vaccinations were proposed and applied to patients at different time of the disease course, explaining heterogenous outcomes. The vaccine products applied were variable according to supplies J o u r n a l P r e -p r o o f with sometimes heterologous second vaccines, though is a limited proportion of patients. Finally, the follow-up remains relatively limited and will need to be updated in the years to come.

Nevertheless, this real-life series of 2391 patients provides important and reassuring information of the protection conferred by vaccines in cancer patients. This analysis indicates however the remaining severity of COVID-19 in cancer patients after vaccination, in marked contrast with HCW of the same hospital. It also indicates that protective measures should be maintained in cancer patients, including consideration of additional third vaccine doses as suggested for immunosuppressed patients (26) (27) (28) (29) (30) , in particular young patients, and those recently treated with anti-CD20. The observation that a documented COVID-19, prior to vaccination is associated with an increased risk of death in the period after vaccination is of concern, and suggest a long term impact of COVID-19 of the natural history of neoplastic diseases. 

Clinical characteristics, outcomes, and risk factors for mortality in patients with cancer and COVID-19 in Hubei, China: a multicentre, retrospective, cohort study

COVID-19 mortality in patients with cancer on chemotherapy or other anticancer treatments: a prospective cohort study

Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study

High mortality rate in cancer patients with symptoms of COVID-19 with or without detectable SARS-COV-2 on RT-PCR

COVID-19 prevalence and mortality in patients with cancer and the effect of primary tumour subtype and patient demographics: a prospective cohort study

GCO-002 CACOVID-19 collaborators/investigators. Risk factors for Coronavirus Disease 2019 (COVID-19) severity and mortality among solid cancer patients and impact of the disease on anticancer treatment: A French nationwide cohort study (GCO-002 CACOVID-19)

Mortality of patients with solid and haematological cancers presenting with symptoms of COVID-19 with vs without detectable SARS-COV-2: a French nationwide prospective cohort study

Association of clinical factors and recent anticancer therapy with COVID-19 severity among patients with cancer: a report from the COVID-19 and Cancer Consortium

Global characteristics and outcomes of SARS-CoV-2 infection in children and adolescents with cancer (GRCCC): a cohort study

Lower detection rates of SARS-COV2 antibodies in cancer patients versus health care workers after symptomatic COVID-19

Prolonged SARS-CoV-2 RNA virus shedding and lymphopenia are hallmarks of COVID-19 in cancer patients with poor prognosis

Immune responses during COVID-19 infection

Systemic pro-inflammatory response identifies patients with cancer with adverse outcomes from SARS-CoV-2 infection: the OnCovid Inflammatory Score

Study of the SARS-CoV-2-specific immune T-cell responses in COVID-19-positive cancer patients

Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine

Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine

Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK

Safety and Efficacy of Single-Dose Ad26.COV2.S Vaccine against Covid-19

Safety and immunogenicity of one versus two doses of the COVID-19 vaccine BNT162b2 for patients with cancer: interim analysis of a prospective observational study

Impaired immunogenicity of BNT162b2 anti-SARS-CoV-2 vaccine in patients treated for solid tumors

Reduced SARS-CoV-2 infection and death after two doses of COVID-19 vaccines in a series of 1503 cancer patients

COVID-19 vaccine efficacy in patients with chronic lymphocytic leukemia

Antibody responses after SARS-CoV-2 vaccination in patients with lymphoma

Serologic response to COVID-19 infection and/or vaccine in cancer patients on active treatment

COVID-19 Vaccines in Cancer Patients

Randomized Trial of a Third Dose of mRNA-1273 Vaccine in Transplant Recipients

Safety and immunogenicity of heterologous versus homologous prime-boost schedules with an adenoviral vectored and mRNA COVID-19 vaccine (Com-COV): a singleblind, randomised, non-inferiority trial

Efficacy of Severe Acute Respiratory Syndrome Coronavirus-2 Vaccine in Patients With Thoracic Cancer: A Prospective Study Supporting a Third Dose in Patients With Minimal Serologic Response After Two Vaccine Doses

Humoral and cellular responses after a third dose of BNT162b2 vaccine in patients treated for lymphoid malignancies medRXiv

Third dose of anti-SARS-CoV-2 vaccine for patients with cancer: Should humoral responses be monitored? A position article

One dose of SARS-CoV-2 vaccine exponentially increases antibodies in individuals who have recovered from symptomatic COVID-19

OnCovid study group. Prevalence and impact of COVID-19 sequelae on treatment and survival of patients with cancer who recovered from SARS-CoV-2 infection: evidence from the OnCovid retrospective, multicentre registry study

Delayed care for patients with newly diagnosed cancer due to COVID-19 and estimated impact on cancer mortality in France

Evaluation of COVID-19 vaccine response in patients with cancer: An interim analysis

Seroconversion rate after vaccination against COVID-19 in cancer patients-a systematic review